Replies to post #3236 on GTC Biotherapeutics (fka GTCB)

[biopearl]

Dew, Any speculation as to the applicability of current or future programs of this technology? Is ACT still a player here? I know they lost some patent fights with GERN. Thanks bp

[DewDiligence]

Notes on Nuclear-Transfer License
from Start Licensing Inc. (Geron)

[Added clarity and fact that AAT herd (as well as ATryn herd) was developed using micro-injection rather than nuclear transfer.]

1. This development is neutral for GTC.

2. GTC had originally licensed the nuclear-transfer patent from Advanced Cell Technology Inc. (ACTC), but ACTC lost a patent case vs Geron and thereby lost ownership of the IP (#msg-13128835).

3. Now, GTC has licensed the same patent from Start Licensing Inc. (an affiliate of Geron) for what is presumably a similar small royalty to what GTC would have owed ACTC.

4. The Geron license has no effect whatsoever on ATryn or GTC’s development program for alpha-1 antitrypsin (AAT) because the ATryn and AAT goat herds were developed using micro-injection rather than nuclear transfer.